首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1283927

非胰島素糖尿病治療藥的全球市場 2023-2027

Global Non-insulin Diabetes Therapeutics Market 2023-2027

出版日期: 2023年05月04日 | 出版商:

TechNavio | 英文 172 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

非胰島素糖尿病治療藥市場在2022-2027年將以10.82％的年複合成長率成長到312億5,155萬美元。

本報告提供非胰島素糖尿病治療藥市場相關資料，整體分析，提供市場規模·預測，趨勢，成長促進因素·課題，網羅了約25家供應商分析等資訊。

同時本報告還提供當前全球市場趨勢與推動因素以及整體市場環境的最新分析。二型糖尿病患病率上升、6-19 歲和 35-50 歲人群糖尿病患病率上升以及近期產品批准推動了該市場的成長。

各地區市場區隔
各地區比較
北美:市場規模與預測 2022-2027
歐洲:市場規模與預測 2022-2027
亞洲:市場規模與預測 2022-2027
全球其他地區:市場規模與預測 2022-2027
美國:市場規模與預測 2022-2027
德國:市場規模與預測 2022-2027
中國:市場規模與預測 2022-2027
英國:市場規模與預測 2022-2027
印度:市場規模與預測 2022-2027
各地區形勢市場機會

第10章促進因素，課題，及趨勢

推動市場要素
市場課題
推動因素與課題的影響
市場趨勢

第11章業者情勢

概要
業者情勢
混亂狀況
產業的風險

第12章供應商分析

交易廠商
供應商的市場定位
Abbott Laboratories
AstraZeneca PLC
Better Therapeutics Inc.
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
F. Hoffmann La Roche Ltd.
GlaxoSmithKline Plc
Johnson and Johnson Services Inc.
Merck KGaA
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
The Cleveland Clinic Foundation

第13章附錄

簡介目錄圖表

Product Code: IRTNTR70604

The non-insulin diabetes therapeutics market is forecasted to grow by USD 31251.55 mn during 2022-2027, accelerating at a CAGR of 10.82% during the forecast period. The report on the non-insulin diabetes therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increasing number of people with type 2 diabetes, the growing prevalence of diabetes among people aged 6-19 and 35-50, and recent product approvals.

Technavio's non-insulin diabetes therapeutics market is segmented as below:

By Type

DPP4 inhibitors
GLP-1 receptor agonists
SGLT2 inhibitors
Others

By Distribution Channel

Offline
Online

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the innovations in therapies as one of the prime reasons driving the non-insulin diabetes therapeutics market growth during the next few years. Also, strategic alliances between vendors and increasing demand for combination drugs will lead to sizable demand in the market.

The report on the non-insulin diabetes therapeutics market covers the following areas:

Non-insulin diabetes therapeutics market sizing
Non-insulin diabetes therapeutics market forecast
Non-insulin diabetes therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-insulin diabetes therapeutics market vendors that include Abbott Laboratories, AstraZeneca PLC, Better Therapeutics Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and The Cleveland Clinic Foundation. Also, the non-insulin diabetes therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global non-insulin diabetes therapeutics market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global non-insulin diabetes therapeutics market 2017 - 2021 ($ million)
4.2 Type Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.3 Distribution Channel Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

6.1 Market segments
Exhibit 30: Chart on Type - Market share 2022-2027 (%)
Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 DPP4 inhibitors - Market size and forecast 2022-2027
Exhibit 34: Chart on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
6.4 GLP-1 receptor agonists - Market size and forecast 2022-2027
Exhibit 38: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
6.5 SGLT2 inhibitors - Market size and forecast 2022-2027
Exhibit 42: Chart on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
6.6 Others - Market size and forecast 2022-2027
Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.7 Market opportunity by Type
Exhibit 50: Market opportunity by Type ($ million)
Exhibit 51: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
Exhibit 52: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibit 53: Data Table on Distribution Channel - Market share 2022-2027 (%)
7.2 Comparison by Distribution Channel
Exhibit 54: Chart on Comparison by Distribution Channel
Exhibit 55: Data Table on Comparison by Distribution Channel
7.3 Offline - Market size and forecast 2022-2027
Exhibit 56: Chart on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Offline - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Offline - Year-over-year growth 2022-2027 (%)
7.4 Online - Market size and forecast 2022-2027
Exhibit 60: Chart on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Online - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Online - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Distribution Channel
Exhibit 64: Market opportunity by Distribution Channel ($ million)
Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 India - Market size and forecast 2022-2027
Exhibit 103: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on India - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 115: Abbott Laboratories - Overview
Exhibit 116: Abbott Laboratories - Business segments
Exhibit 117: Abbott Laboratories - Key news
Exhibit 118: Abbott Laboratories - Key offerings
Exhibit 119: Abbott Laboratories - Segment focus
12.4 AstraZeneca PLC
Exhibit 120: AstraZeneca PLC - Overview
Exhibit 121: AstraZeneca PLC - Product / Service
Exhibit 122: AstraZeneca PLC - Key news
Exhibit 123: AstraZeneca PLC - Key offerings
12.5 Better Therapeutics Inc.
Exhibit 124: Better Therapeutics Inc. - Overview
Exhibit 125: Better Therapeutics Inc. - Product / Service
Exhibit 126: Better Therapeutics Inc. - Key news
Exhibit 127: Better Therapeutics Inc. - Key offerings
12.6 Boehringer Ingelheim International GmbH
Exhibit 128: Boehringer Ingelheim International GmbH - Overview
Exhibit 129: Boehringer Ingelheim International GmbH - Business segments
Exhibit 130: Boehringer Ingelheim International GmbH - Key news
Exhibit 131: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 132: Boehringer Ingelheim International GmbH - Segment focus
12.7 Eli Lilly and Co.
Exhibit 133: Eli Lilly and Co. - Overview
Exhibit 134: Eli Lilly and Co. - Product / Service
Exhibit 135: Eli Lilly and Co. - Key news
Exhibit 136: Eli Lilly and Co. - Key offerings
12.8 F. Hoffmann La Roche Ltd.
Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 142: GlaxoSmithKline Plc - Overview
Exhibit 143: GlaxoSmithKline Plc - Business segments
Exhibit 144: GlaxoSmithKline Plc - Key news
Exhibit 145: GlaxoSmithKline Plc - Key offerings
Exhibit 146: GlaxoSmithKline Plc - Segment focus
12.10 Johnson and Johnson Services Inc.
Exhibit 147: Johnson and Johnson Services Inc. - Overview
Exhibit 148: Johnson and Johnson Services Inc. - Business segments
Exhibit 149: Johnson and Johnson Services Inc. - Key news
Exhibit 150: Johnson and Johnson Services Inc. - Key offerings
Exhibit 151: Johnson and Johnson Services Inc. - Segment focus
12.11 Merck KGaA
Exhibit 152: Merck KGaA - Overview
Exhibit 153: Merck KGaA - Business segments
Exhibit 154: Merck KGaA - Key news
Exhibit 155: Merck KGaA - Key offerings
Exhibit 156: Merck KGaA - Segment focus
12.12 Novartis AG
Exhibit 157: Novartis AG - Overview
Exhibit 158: Novartis AG - Business segments
Exhibit 159: Novartis AG - Key offerings
Exhibit 160: Novartis AG - Segment focus
12.13 Novo Nordisk AS
Exhibit 161: Novo Nordisk AS - Overview
Exhibit 162: Novo Nordisk AS - Business segments
Exhibit 163: Novo Nordisk AS - Key offerings
Exhibit 164: Novo Nordisk AS - Segment focus
12.14 Pfizer Inc.
Exhibit 165: Pfizer Inc. - Overview
Exhibit 166: Pfizer Inc. - Product / Service
Exhibit 167: Pfizer Inc. - Key news
Exhibit 168: Pfizer Inc. - Key offerings
12.15 Sanofi SA
Exhibit 169: Sanofi SA - Overview
Exhibit 170: Sanofi SA - Business segments
Exhibit 171: Sanofi SA - Key news
Exhibit 172: Sanofi SA - Key offerings
Exhibit 173: Sanofi SA - Segment focus
12.16 Takeda Pharmaceutical Co. Ltd.
Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 176: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 177: Takeda Pharmaceutical Co. Ltd. - Key offerings
12.17 The Cleveland Clinic Foundation
Exhibit 178: The Cleveland Clinic Foundation - Overview
Exhibit 179: The Cleveland Clinic Foundation - Product / Service
Exhibit 180: The Cleveland Clinic Foundation - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 181: Inclusions checklist
Exhibit 182: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 183: Currency conversion rates for US$
13.4 Research methodology
Exhibit 184: Research methodology
Exhibit 185: Validation techniques employed for market sizing
Exhibit 186: Information sources
13.5 List of abbreviations
Exhibit 187: List of abbreviations

簡介目錄圖表

Exhibits:

Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Type
Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size - Data Table on global non-insulin diabetes therapeutics market 2017 - 2021 ($ million)
Exhibits19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
Exhibits20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits23: Five forces analysis - Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition - Five forces 2022 and 2027
Exhibits30: Chart on Type - Market share 2022-2027 (%)
Exhibits31: Data Table on Type - Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits46: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibits47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibits48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibits49: Data Table on Others - Year-over-year growth 2022-2027 (%)
Exhibits50: Market opportunity by Type ($ million)
Exhibits51: Data Table on Market opportunity by Type ($ million)
Exhibits52: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibits53: Data Table on Distribution Channel - Market share 2022-2027 (%)
Exhibits54: Chart on Comparison by Distribution Channel
Exhibits55: Data Table on Comparison by Distribution Channel
Exhibits56: Chart on Offline - Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Offline - Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Offline - Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Online - Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Online - Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Online - Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Online - Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Distribution Channel ($ million)
Exhibits65: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on India - Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity By Geographical Landscape ($ million)
Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: Abbott Laboratories - Overview
Exhibits116: Abbott Laboratories - Business segments
Exhibits117: Abbott Laboratories - Key news
Exhibits118: Abbott Laboratories - Key offerings
Exhibits119: Abbott Laboratories - Segment focus
Exhibits120: AstraZeneca PLC - Overview
Exhibits121: AstraZeneca PLC - Product / Service
Exhibits122: AstraZeneca PLC - Key news
Exhibits123: AstraZeneca PLC - Key offerings
Exhibits124: Better Therapeutics Inc. - Overview
Exhibits125: Better Therapeutics Inc. - Product / Service
Exhibits126: Better Therapeutics Inc. - Key news
Exhibits127: Better Therapeutics Inc. - Key offerings
Exhibits128: Boehringer Ingelheim International GmbH - Overview
Exhibits129: Boehringer Ingelheim International GmbH - Business segments
Exhibits130: Boehringer Ingelheim International GmbH - Key news
Exhibits131: Boehringer Ingelheim International GmbH - Key offerings
Exhibits132: Boehringer Ingelheim International GmbH - Segment focus
Exhibits133: Eli Lilly and Co. - Overview
Exhibits134: Eli Lilly and Co. - Product / Service
Exhibits135: Eli Lilly and Co. - Key news
Exhibits136: Eli Lilly and Co. - Key offerings
Exhibits137: F. Hoffmann La Roche Ltd. - Overview
Exhibits138: F. Hoffmann La Roche Ltd. - Business segments
Exhibits139: F. Hoffmann La Roche Ltd. - Key news
Exhibits140: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits141: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits142: GlaxoSmithKline Plc - Overview
Exhibits143: GlaxoSmithKline Plc - Business segments
Exhibits144: GlaxoSmithKline Plc - Key news
Exhibits145: GlaxoSmithKline Plc - Key offerings
Exhibits146: GlaxoSmithKline Plc - Segment focus
Exhibits147: Johnson and Johnson Services Inc. - Overview
Exhibits148: Johnson and Johnson Services Inc. - Business segments
Exhibits149: Johnson and Johnson Services Inc. - Key news
Exhibits150: Johnson and Johnson Services Inc. - Key offerings
Exhibits151: Johnson and Johnson Services Inc. - Segment focus
Exhibits152: Merck KGaA - Overview
Exhibits153: Merck KGaA - Business segments
Exhibits154: Merck KGaA - Key news
Exhibits155: Merck KGaA - Key offerings
Exhibits156: Merck KGaA - Segment focus
Exhibits157: Novartis AG - Overview
Exhibits158: Novartis AG - Business segments
Exhibits159: Novartis AG - Key offerings
Exhibits160: Novartis AG - Segment focus
Exhibits161: Novo Nordisk AS - Overview
Exhibits162: Novo Nordisk AS - Business segments
Exhibits163: Novo Nordisk AS - Key offerings
Exhibits164: Novo Nordisk AS - Segment focus
Exhibits165: Pfizer Inc. - Overview
Exhibits166: Pfizer Inc. - Product / Service
Exhibits167: Pfizer Inc. - Key news
Exhibits168: Pfizer Inc. - Key offerings
Exhibits169: Sanofi SA - Overview
Exhibits170: Sanofi SA - Business segments
Exhibits171: Sanofi SA - Key news
Exhibits172: Sanofi SA - Key offerings
Exhibits173: Sanofi SA - Segment focus
Exhibits174: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibits175: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibits176: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibits177: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibits178: The Cleveland Clinic Foundation - Overview
Exhibits179: The Cleveland Clinic Foundation - Product / Service
Exhibits180: The Cleveland Clinic Foundation - Key offerings
Exhibits181: Inclusions checklist
Exhibits182: Exclusions checklist
Exhibits183: Currency conversion rates for US$
Exhibits184: Research methodology
Exhibits185: Validation techniques employed for market sizing
Exhibits186: Information sources
Exhibits187: List of abbreviations